In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Public offering nets $549mm for Seattle Genetics

29 Jul 2019

Executive Summary

Seattle Genetics Inc. netted $549mm through a public offering of 8.2mm common shares (including the overallotment) at $70. The company develops and sells cancer therapies, and will use the proceeds to support ongoing commercialization activities in the US and Canada for Adcetris (brentuximab vedotin, indicated for various lymphomas); for the potential upcoming launch of enfortumab vedotin (in Phase II for bladder cancer); and for additional R&D and corporate needs.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By